These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
Pipeline and key clinical candidates for these companies:
Connect Biopharma is a U.S. and China-based clinical-stage biopharmaceutical company focused on treating inflammatory diseases with therapies derived from T cell research. The company's lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis and asthma. The company's second most advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis, or UC. The company's third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with atopic dermatitis, or AD.
Bellicum is a clinical stage biopharmaceutical company whose "next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies," the company has stated. Bellicum's GoCAR-T product candidates, BPX-601 and BPX-603, are "designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms."
CNS Pharmaceuticals is developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme, or GBM, an aggressive and incurable form of brain cancer.
Recent news on these stocks:
In a regulatory filing, Bellicum disclosed that it provided notices to Richard Fair, president and CEO, and Charity Scripture, Chief Development Officer that their employment by the company will terminate on June 30. In connection with the termination of Fair's employment, he will receive severance benefits in accordance with his employment agreement.
Connect Biopharma Holdings Limited announced positive data at Week 48 from Phase 2 trial CN002 for icanbelimod, a once-daily, orally administered, selective sphingosine 1-phosphate receptor 1 modulator in development for the treatment of ulcerative colitis UC ..."Current treatment options for UC have not demonstrated break-through efficacy based on clinical remission, highlighting the need for new and more effective therapies. Based on the icanbelimod 0.2 mg data, the clinical remission efficacy, safety data and absolute lymphocyte count reduction are compelling," said Brian Feagan, M.D., Professor in the Departments of Medicine, Epidemiology and Biostatistics at the Shulich School of Medicine & Dentistry, University of Western Ontario. "Additionally, because icanbelimod has rapid recovery of lymphocytes upon discontinuation and high potency, there is an opportunity to optimize the dosing strategy in future trials to further enhance the already encouraging efficacy data," added Dr. Feagan."These promising data from the maintenance period of CN002 further support the potential of icanbelimod to be not only a best-in-class S1P1 modulator, but also an important new treatment option among current standard of care therapies, offering patients with UC a much-needed sustainable control of inflammation," said Zheng Wei, Ph.D., Co-Founder and CEO of Connect Biopharma. "We are actively exploring strategic partnerships to advance icanbelimod into a registrational program to realize its therapeutic potential. In addition, we plan to submit the full data from the study to a medical congress later this year."
CNS Pharmaceuticals announced that its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent glioblastoma multiforme, GBM, an aggressive and incurable form of brain cancer, has enrolled 134 patients, representing more than 50% of the total planned enrollment for the study. "The achievement of this milestone in any study is no small feat. The dedication of our team and the proficiency of their operational execution continues to be shown by reaching over 50% of the total planned enrollment in our study. This is an important step that brings us closer to providing a potential treatment option to patients with GBM and addressing this disease, which remains a significant unmet need. We are focused on continuing this momentum towards the interim analysis for the study, which remains on target for the third quarter of this year," commented John Climaco, CEO of CNS Pharmaceuticals.
Hear more from InvestingChannel by signing up for The Spill.
About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel's online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.